Ignite Creation Date:
2024-05-05 @ 4:41 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00298064
Status:
WITHDRAWN
Last Update Posted:
2023-07-05
First Post:
2006-02-28
Brief Title:
Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer
Sponsor:
University of New Mexico
Organization:
University of New Mexico
Study Overview
Official Title:
Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer
Status:
WITHDRAWN
Status Verified Date:
2023-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The Tissue Repository will search for cases pull slides Paraffin-embedded tissue PET blocks
Detailed Description:
This study is done to gather preliminary data for determining the best way to test EGFR expression in patients with cervical cancer who will receive treatment with EGFR inhibitors in the future
This study is designed to obtain preliminary data of genomic and phenotypic alterations of the EGFR pathway in high grade cervical intraepithelial lesions HG-SIL and invasive cervical cancers CC to be used later for therapeutic guidance and to evaluate genomic over-expression amplification point mutations etc and phenotypic alterations of other transduction pathways interacting with the EGFR pathway
This study is designed to obtain preliminary data of genomic and phenotypic alterations of the EGFR pathway in high grade cervical intraepithelial lesions HG-SIL and invasive cervical cancers CC to be used later for therapeutic guidance and to evaluate genomic over-expression amplification point mutations etc and phenotypic alterations of other transduction pathways interacting with the EGFR pathway
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None